Mineralocorticoid receptor antagonists: their use and differentiation in Japan

• Published in: Hypertension research Vol. 36; no. 3; pp. 185 - 190
• Main Author: Sato, Atsuhisa
• Format: Journal Article
• Language: English
• Published: England 01-03-2013
• Subjects: Comorbidity; Contraindications; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Hypertension - drug therapy; Hypertension - epidemiology; Japan; Mineralocorticoid Receptor Antagonists - adverse effects; Mineralocorticoid Receptor Antagonists - therapeutic use; Spironolactone - adverse effects; Spironolactone - analogs & derivatives; Spironolactone - therapeutic use; Treatment Outcome
• ISSN: 0916-9636; 1348-4214
• DOI: 10.1038/hr.2012.182

In the presence of salt, aldosterone causes hypertension and organ damage via the mineralocorticoid receptor (MR) through various mechanisms. MR antagonists are considered to be potassium-sparing diuretics that exert their effect by blocking MR in the kidney, and they are not the first choice for treating hypertension. However, the importance and usefulness of inhibiting aldosterone in the management of hypertension have recently been revealed in both the basic and clinical fields. In Japan, both the selective MR antagonist eplerenone and the non-selective MR antagonist spironolactone are indicated for the treatment of hypertension. Although these drugs are generally used in the same manner, in some cases they require differentiation. This differentiation is divided into two types due to the differences in their features and differences in their contraindications in Japan. Based on a number of studies on MR antagonists that have been recently published, the diseases and clinical conditions targeted by MR antagonists appear to be likely to increase in the future. In Japan, we consider it necessary to carefully differentiate spironolactone from eplerenone in regard to their intended uses.